William M Ridgway Selected Research

Transforming Growth Factor beta Receptors (TGF beta Receptors)

1/2018	Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis.
10/2012	The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice.
7/2010	Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis.
5/2010	Murine models of autoimmune cholangitis.
3/2009	B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis.
6/2008	Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice.
2/2008	Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis.
8/2006	Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William M Ridgway Research Topics

Disease

16	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2022 - 08/2006
15	Cholangitis 01/2021 - 01/2007
11	Inflammation (Inflammations) 11/2021 - 09/2007
9	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2021 - 08/2004
5	Autoimmune Diseases (Autoimmune Disease) 11/2021 - 01/2012
5	Liver Diseases (Liver Disease) 01/2017 - 08/2004
5	Colitis 01/2014 - 03/2009
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2014 - 06/2008
2	COVID-19 11/2020 - 01/2020
2	Infections 01/2020 - 07/2011
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 02/2013
2	Myositis (Idiopathic Inflammatory Myopathies) 08/2013 - 12/2012
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	Rheumatoid Arthritis 11/2021
1	Coronavirus Infections 01/2020
1	Rheumatic Diseases (Rheumatism) 01/2020
1	Sclerosing Cholangitis 01/2020
1	Cytokine Release Syndrome 01/2020
1	Insulin Resistance 09/2017
1	Genetic Predisposition to Disease (Genetic Predisposition) 08/2014
1	Virus Diseases (Viral Diseases) 05/2014
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2012
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2012
1	Cysts 01/2011
1	Acute Liver Failure (Fulminant Hepatic Failure) 07/2010
1	Body Weight (Weight, Body) 01/2009
1	Pneumonia (Pneumonitis) 09/2007
1	Interstitial Lung Diseases (Interstitial Lung Disease) 09/2007
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 02/2006
1	Bacterial Infections (Bacterial Infection) 01/2006
1	Biliary Tract Diseases 08/2004

Drug/Important Bio-Agent (IBA)

9	AntibodiesIBA 08/2014 - 08/2006
8	CytokinesIBA 11/2021 - 01/2009
8	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 01/2018 - 08/2006
6	Insulin (Novolin)FDA Link 01/2017 - 08/2004
6	AutoantibodiesIBA 01/2017 - 08/2004
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2021 - 06/2008
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 02/2006
3	AntigensIBA 05/2014 - 01/2007
3	Interleukin-17 (Interleukin 17)IBA 01/2014 - 07/2011
3	Histidine-tRNA LigaseIBA 08/2013 - 09/2007
2	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2021
2	Immunoglobulins (Immunoglobulin)IBA 05/2021 - 01/2009
2	Immunoglobulin G (IgG)IBA 05/2021 - 12/2012
2	XenobioticsIBA 08/2014 - 01/2006
2	InterleukinsIBA 02/2013 - 10/2012
2	RezafunginIBA 07/2011 - 07/2011
2	Interleukin-6 (Interleukin 6)IBA 07/2010 - 03/2009
2	Interleukin-2 Receptor alpha SubunitIBA 05/2010 - 01/2009
2	Interferon-gamma (Interferon, gamma)IBA 08/2008 - 06/2008
1	Pyruvate Dehydrogenase Complex (Dehydrogenase Complex, Pyruvate)IBA 01/2022
1	AutoantigensIBA 10/2021
1	Peptides (Polypeptides)IBA 10/2021
1	Enoxacin (AT 2266)FDA Link 01/2021
1	VaccinesIBA 11/2020
1	Immunomodulating AgentsIBA 11/2020
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Antimalarials (Antimalarial Agents)IBA 01/2020
1	Peptide Hydrolases (Proteases)FDA Link 01/2020
1	Polysaccharides (Glycans)IBA 01/2020
1	SugarsIBA 01/2020
1	Antirheumatic Agents (DMARD)IBA 01/2020
1	tocilizumab (atlizumab)FDA Link 01/2020
1	4-1BB Ligand (4 1BB Ligand)IBA 01/2020
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 09/2017
1	Liraglutide FDA Link 09/2017
1	ChemokinesIBA 01/2017
1	Chemokine ReceptorsIBA 01/2017
1	Monoclonal AntibodiesIBA 10/2015
1	Biological ProductsIBA 05/2015
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 08/2013
1	Transforming Growth Factors (Transforming Growth Factor)IBA 02/2013
1	Interleukin-12 (IL 12)IBA 10/2012
1	Interleukin-23 (Interleukin 23)IBA 10/2012
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 07/2010
1	Therapeutic UsesIBA 07/2010
1	Concanavalin AIBA 07/2010
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 05/2010
1	EpitopesIBA 08/2008
1	2-octynoic acidIBA 08/2008
1	EnzymesIBA 05/2008
1	Dihydrolipoyllysine-Residue Acetyltransferase (Dihydrolipoyl Transacetylase)IBA 05/2008
1	Ligases (Synthetase)IBA 09/2007
1	fas Receptor (CD95 Antigen)IBA 01/2007
1	Small Nuclear Ribonucleoproteins (snRNP)IBA 02/2006

Therapy/Procedure

5	Therapeutics 01/2021 - 01/2014
2	Biological Therapy 01/2021 - 01/2020
1	Immunotherapy 10/2021
1	Drug Therapy (Chemotherapy) 01/2012